Short-Term Debt to Equity Ratio: Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals (SUPN) is implementing autonomous systems for high-precision component mixing and the packaging of neurotherapy agents. Stringent regulatory requirements and patent protection for substance transport methods create a high barrier to entry in the industry. This price chart shows that the indicator stands at 0.00. The business is based on intellectual assets, utilizing outsourced production to minimize capital expenditures and increase profits.
Analytical breakdowns and data insights for company supernus.com (SUPN)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity Supernus Pharmaceuticals|SUPN - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio Supernus|SUPN - Company Aggregate Debts|Debt to Book Capitalization Ratio Supernus Pharmaceuticals, Inc.|SUPN - Long-Term Liabilities|Company Short-Term Debts Supernus|Quick Liquidity supernus.com
- company profitability and valuation multiples indicators:
Comprehensive company analysis:SUPN Supernus Pharma
This ratio compares obligations with a maturity of over one year to total capital, allowing for a real-time assessment of financial stability and the risk of liquidity shortages. For Supernus Pharmaceuticals (SUPN), which invests in complex CNS drug delivery technologies, the proportion of short-term loans to capital serves as an indicator of the balance between aggressive innovation development and the maintenance of solvency.
Competitor analysis for Supernus Pharmaceuticals
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Catalyst Corp (CPRX)|Short-Term Debt to Equity Denali Therapeutics|harmonybiosciences.com (HRMY) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio BHVN (Biohaven)|Short-Term Debt to Capital Amylyx Pharmaceuticals Inc (AMLX)|Short-Term Debt to Equity Trevi Pharma TRVI|PRAX (Praxis Corp) - Current Liabilities to Equity|Anavex Life Sciences - Short-Term Debt to Capital|Current Liabilities to Capital ceribell.com|Prothena Corp (PRTA) - Short-Term Debt to Equity|Alector - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Annexon Inc.|Short-Term Debt to Capital Ratio OMER (Omeros Corp.)|Short-Term Debt to Equity Ratio NGNE (Neurogene Inc.)|Short-Term Debt to Capital acimmune.com (ACIU)|Short-Term Debt to Equity Voyager Therapeutics, Inc. VYGR|Short-Term Debt to Capital Coefficient Neumora (NMRA)|SCLX: Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital TVGN (Tevogen Bio Inc.)|alphacognition.com (ACOG) - Short-Term Debt to Equity|Current Liabilities to Equity CGTX (cogrx.com)|IKT (Inhibikase Therapeutics, Inc.) - Short-Term Debt to Capital|SAVA: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Capital ASRT|Short-Term Debt to Capital coyatherapeutics.com (COYA)|Short-Term Debt to Equity Vistagen VTGN|Ratio of Short-Term Indebtedness to Capital OVID|ABOS - Short-Term Debt to Equity|CervoMed, Inc. (CRVO) - Short-Term Debt to Equity Ratio|ATHE: Short-Term Debt to Capital|Clene (CLNN) - Short-Term Debt to Capital|PEPG (PepGen Inc) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio jupiterneurosciences.com (JUNS)|Short-Term Debt to Capital RLMD|ANVS - Current Liabilities to Capital|Grace Therapeutics - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital Firefly Neuro AIFF|KLTO: Short-Term Debt to Equity Ratio|NeuroSense Therapeutics - Short-Term Loans to Capital Ratio|RVPH: Short-Term Debt to Capital|MTVA - Short-Term Debt to Capital Coefficient|NRXS (NeurAxis, Inc) - Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Helius Medical Technologies Inc. (HSDT)|Short-Term Debt to Capital PASG|Short-Term Debt to Capital bionomics.com.au (NEUP)|Short-Term Debt to Equity Minerva Neurosciences, Inc. NERV|Athira Pharma Inc - Short-Term Debt to Equity|ADXN - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient Alzamend Neuro, Inc. ALZN|cyclerion.com (CYCN) - Short-Term Debt to Equity|PTIX - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio KTTA|Short-Term Debt to Capital Cortigent Medical|Short-Term Debt to Equity Avenue Therapeutics, Inc (ATXI)|BCLI: Current Liabilities to Equity|Short-Term Debt to Equity Cara Therapeutics, Inc. CARA|CHRO: Short-Term Debt to Capital Ratio|ELYM - Short-Term Debt to Equity|ITCI (Intra-Cellular Therapies) - Short-Term Debt to Capital Ratio|LBPH: Short-Term Debt to Capital|Current Liabilities to Capital Marinus Pharma (MRNS)|Short-Term Debt to Equity Ratio NKGN|Short-Term Debt to Capital neurobopharma.com|Short-Term Debt to Equity Sage Therapeutics (SAGE)|SNPX (Synaptogenix Inc.) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Trevena, Inc TRVN|Vigil Neuroscience Inc. (VIGL) - Current Liabilities to Capital|WENA - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient cerevel.com CERE